Inventiva to host a webcast with Key Opinion Leaders following the
EASL International Liver Congress™ 2022
- Update on Inventiva’s NATiV3 Phase III clinical trial
evaluating lanifibranor in patients with NASH and fibrosis (stage
F2/F3) non-cirrhotic by Prof. Sven Francque
- Update on the current NASH landscape by Dr. Stephen
Harrison
- Presentation by Dr. Michael Cooreman of three scientific
abstracts from NATIVE selected for poster presentations at the EASL
International Liver Congress™ 2022
- Update on LEGEND, Inventiva’s Phase IIa combination study with
lanifibranor and SGLT2 inhibitor empagliflozin in patients with
non-cirrhotic NASH and T2D, by Dr. Onno Holleboom
- Virtual webcast event to take place on June 28, 2022, at 10:00
am (ET) / 4:00 pm (CET)
Daix (France), Long
Island City (New York, United States), June 16, 2022 –
Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage
biopharmaceutical company focused on the development of oral small
molecule therapies for the treatment of non-alcoholic
steatohepatitis (NASH) and other diseases with significant unmet
medical needs, announced today that it will host a webcast event
focused on NASH with the participation of three Key Opinion Leaders
(KOLs) on June 28, 2022, following the EASL International Liver
Congress™ 2022.
Following an introduction from Frédéric Cren,
Chairman, CEO and cofounder of Inventiva, and Pierre Broqua, Chief
Scientific Officer and cofounder of Inventiva, the event will
feature three scientific abstracts presented at the EASL
International Liver Congress™ 2022, as well as three presentations
focused on the latest news around the development of lanifibranor
and various aspects related to NASH. The program will include
dedicated Q&A sessions.
The agenda is as follows:
Corporate update
Speakers: Frederic Cren, CEO and cofounder of
Inventiva Pharma and Pierre Broqua, Chief Scientific Officer and
cofounder of Inventiva Pharma
Update on Inventiva’s NATiV3 Phase III clinical trial in
NASH
Speaker: Prof. Sven Francque, Chairman of the
Department of Gastroenterology and Hepatology of the University
Hospital Antwerp
Update on the NASH field
Speaker: Dr. Steven Harrison, Medical Director
for Pinnacle Clinical Research and the President of Summit Clinical
Research
Overview of the scientific abstracts presented during
the EASL International Liver Congress™ 2022Speakers: Dr.
Michael Cooreman, Chief Medical Officer of Inventiva Pharma
Abstract #1: |
"The pan-PPAR agonist lanifibranor improves markers of
cardiometabolic health in patients with NASH independent of weight
change." |
Abstract #2: |
"Lanifibranor therapy reduces the FibroScan-aspartate
aminotransferase (FastTM) score associated with histological 'NASH
resolution and improvement of fibrosis' and biomarker
response." |
Abstract #3: |
"Identification of biomarkers of histological response in patients
with non-cirrhotic NASH treated with Lanifibranor." |
Update on LEGEND, Phase IIa combination
study with lanifibranor and SGLT2 inhibitor empaglifozin in
patients with NASH and T2DSpeaker: Dr. Onno Holleboom,
Internist, faculty member & Principal Investigator, Amsterdam
University Medical Center
The details to connect to the webcast are as follows:
Date: |
Tuesday, June 28,
2022 |
Time: |
10:00 am - 12:00
pm (ET) / 4:00 pm - 6:00 pm (CET) |
Registration: |
Inventiva KOL's
event Registration |
The presentation document and the link to the
webcast (live and replay) will also be available on Inventiva’s
website in the “Investors – Investor Presentations” section:
http://inventivapharma.com/investors/investor-presentations/.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of NASH and other diseases
with significant unmet medical need. The Company benefits from a
strong expertise and experience in the domain of compounds
targeting nuclear receptors, transcription factors and epigenetic
modulation. Inventiva’s lead product candidate, lanifibranor, is
currently in a pivotal Phase III clinical trial, NATiV3, for the
treatment of adult patients with NASH, a common and progressive
chronic liver disease for which there are currently no approved
therapies.
The Company has established a strategic
collaboration with AbbVie in the area of autoimmune diseases that
resulted in the discovery of the drug candidate cedirogant
(ABBV-157), an oral RORγ inverse agonist which is being evaluated
in a Phase IIb clinical trial, led by AbbVie, in adult patients
with moderate to severe chronic plaque psoriasis. Inventiva’s
pipeline also includes odiparcil, a drug candidate for the
treatment of adult mucopolysaccharidoses (MPS) VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended clinical efforts relating
to odiparcil and is reviewing available options with respect to its
potential further development. Inventiva is in the process of
selecting an oncology development candidate for its Hippo signaling
pathway program.
The Company has a scientific team of
approximately 80 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com.
Contacts
InventivaPascaline ClercVP of Global External
Affairs media@inventivapharma.com+1 240 620 9175 |
Brunswick GroupLaurence Frost / Tristan Roquet
Montegon / Aude LepreuxMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke,
an ICR CompanyPatricia L. Bank Investor
relationspatti.bank@westwicke.com+1 415 513 1284 |
|
|
|
Important Notice
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release are forward-looking statements. These statements include,
but are not limited to, forecasts and estimates with respect to
Inventiva’s pre-clinical programs and clinical trials, including
recruitment for those trial, clinical trial data releases,
including for part 1 of the Phase III clinical trial of
lanifibranor in patients with NASH and two Phase II trials in
patients with NAFLD and type 2 diabetes, and in combination with
empagliflozine, pipeline and preclinical and clinical development
plans, milestone payments, royalties and product sales, future
activities, expectations, plans, growth and prospects of Inventiva
and the sufficiency of Inventiva’s cash resources and cash runway.
Certain of these statements, forecasts and estimates can be
recognized by the use of words such as, without limitation,
“believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”,
“estimates”, “may”, “will”, “would”, “could”, “might”, “should”,
“plans”, and “continue” and similar expressions. Such statements
are not historical facts but rather are statements of future
expectations and other forward-looking statements that are based on
management's beliefs. These statements reflect such views and
assumptions prevailing as of the date of the statements and involve
known and unknown risks and uncertainties that could cause future
results, performance or future events to differ materially from
those expressed or implied in such statements. Future events are
difficult to predict and may depend upon factors that are beyond
Inventiva's control. There can be no guarantees with respect to
pipeline product candidates that the clinical trial results will be
available on their anticipated timeline, that future clinical
trials will be initiated as anticipated, that product candidates
will receive the necessary regulatory approvals, or that any of the
anticipated milestones by Inventiva or its partners will be reached
on their expected timeline, or at all. Actual results may turn out
to be materially different from the anticipated future results,
performance or achievements expressed or implied by such
statements, forecasts and estimates, due to a number of factors,
including that Inventiva is a clinical-stage company with no
approved products and no historical product revenues, Inventiva has
incurred significant losses since inception, Inventiva has a
limited operating history and has never generated any revenue from
product sales, Inventiva will require additional capital to finance
its operations, Inventiva's future success is dependent on the
successful clinical development, regulatory approval and subsequent
commercialization of current and any future product candidates,
preclinical studies or earlier clinical trials are not necessarily
predictive of future results and the results of Inventiva's
clinical trials may not support Inventiva's product candidate
claims, Inventiva may encounter substantial delays in its clinical
trials or Inventiva may fail to demonstrate safety and efficacy to
the satisfaction of applicable regulatory authorities, enrolment
and retention of patients in clinical trials is an expensive and
time-consuming process and could be made more difficult or rendered
impossible by multiple factors outside Inventiva's control,
Inventiva's product candidates may cause adverse drug reactions or
have other properties that could delay or prevent their regulatory
approval, or limit their commercial potential, Inventiva faces
substantial competition and Inventiva’s business, and preclinical
studies and clinical development programs and timelines, its
financial condition and results of operations could be materially
and adversely affected by the current COVID-19 pandemic and
geopolitical events, such as the conflict between Russia and
Ukraine and related impacts and potential impacts on the
initiation, enrolment and completion of Inventiva’s clinical trials
on anticipated timelines. Given these risks and uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as
of the date of this press release. Readers are cautioned not to
place undue reliance on any of these forward-looking
statements.
Please refer to the Universal Registration
Document for the year ended December 31, 2021 filed with the
Autorité des Marchés Financiers on March 11, 2022 and the Annual
Report on Form 20-F for the year ended December 31, 2021 filed with
the Securities and Exchange Commission on March 11, 2022 for
additional information in relation to such factors, risks and
uncertainties.
All information in this press release is as of
the date of the release. Except as required by law, Inventiva has
no intention and is under no obligation to update or review the
forward-looking statements referred to above.
- Inventiva - PR - EASL KOL event- EN - 16 06 2022
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024